Combination products: adapting the EU regulatory framework to reality
This article was originally published in SRA
Shayesteh Fürst-Ladani says that EU rules on combination healthcare products must avoid duplication of evidence gathering and of regulatory submissions and provide opportunities for early dialogue between stakeholders.
You may also be interested in...
Succeeding in Switzerland's regulatory environment for pharma - similarities and differences compared with the EU
Shayesteh Fürst-Ladani highlights critical differences between the Swiss and EU regulatory systems that drug manufacturers should be aware of and discusses how Swissmedic plans to shorten its review timelines.